Protalix BioTherapeutics (NYSE:PLX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Protalix BioTherapeutics (NYSE:PLXGet Rating) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating on the stock.

Protalix BioTherapeutics Trading Up 1.9 %

Shares of NYSE:PLX opened at $1.05 on Monday. The company has a fifty day simple moving average of $1.05 and a 200 day simple moving average of $1.09. The firm has a market cap of $52.24 million, a PE ratio of -2.69 and a beta of 1.61. Protalix BioTherapeutics has a 12-month low of $0.70 and a 12-month high of $2.00.

Protalix BioTherapeutics (NYSE:PLXGet Rating) last released its earnings results on Monday, August 15th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.07. The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $2.68 million. As a group, equities research analysts forecast that Protalix BioTherapeutics will post -0.48 EPS for the current fiscal year.

About Protalix BioTherapeutics

(Get Rating)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

Read More

Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.